Joseph M. Gozgit

2.2k total citations
25 papers, 1.1k citations indexed

About

Joseph M. Gozgit is a scholar working on Genetics, Molecular Biology and Oncology. According to data from OpenAlex, Joseph M. Gozgit has authored 25 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Genetics, 9 papers in Molecular Biology and 9 papers in Oncology. Recurrent topics in Joseph M. Gozgit's work include Chronic Myeloid Leukemia Treatments (9 papers), Chronic Lymphocytic Leukemia Research (6 papers) and Click Chemistry and Applications (5 papers). Joseph M. Gozgit is often cited by papers focused on Chronic Myeloid Leukemia Treatments (9 papers), Chronic Lymphocytic Leukemia Research (6 papers) and Click Chemistry and Applications (5 papers). Joseph M. Gozgit collaborates with scholars based in United States, United Kingdom and Italy. Joseph M. Gozgit's co-authors include Victor M. Rivera, Tim Clackson, Frank Wang, Scott Wardwell, Narayana I. Narasimhan, Qurish K. Mohemmad, Matthew J. Wong, William C. Shakespeare, Kathleen F. Arcaro and Brian T. Pentecost and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Blood.

In The Last Decade

Joseph M. Gozgit

25 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Joseph M. Gozgit United States	13	580	282	265	209	179	25	1.1k
Kevin Yee United States	9	480 0.8×	303 1.1×	362 1.4×	499 2.4×	267 1.5×	12	1.2k
Paola Aimone Switzerland	17	372 0.6×	549 1.9×	338 1.3×	235 1.1×	229 1.3×	43	1.1k
Ramamoorthy Nagasubramanian United States	11	357 0.6×	365 1.3×	437 1.6×	106 0.5×	216 1.2×	31	1.1k
Steven Novick United States	16	819 1.4×	437 1.5×	131 0.5×	645 3.1×	362 2.0×	28	1.4k
Keigo Yorozu United States	18	285 0.5×	566 2.0×	289 1.1×	113 0.5×	91 0.5×	52	1.0k
Fabien Calvo France	7	761 1.3×	345 1.2×	199 0.8×	167 0.8×	110 0.6×	13	1.4k
Nicole Watson Australia	14	199 0.3×	242 0.9×	307 1.2×	567 2.7×	465 2.6×	23	1.3k
Noreen Fulton United States	20	457 0.8×	460 1.6×	82 0.3×	225 1.1×	105 0.6×	42	1.2k
Jan J. Koornstra Netherlands	18	413 0.7×	524 1.9×	463 1.7×	217 1.0×	60 0.3×	32	1.5k
Kaname Yamashita Japan	15	411 0.7×	442 1.6×	150 0.6×	93 0.4×	49 0.3×	51	976

Countries citing papers authored by Joseph M. Gozgit

Since Specialization

Citations

This map shows the geographic impact of Joseph M. Gozgit's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joseph M. Gozgit with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joseph M. Gozgit more than expected).

Fields of papers citing papers by Joseph M. Gozgit

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joseph M. Gozgit. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joseph M. Gozgit. The network helps show where Joseph M. Gozgit may publish in the future.

Co-authorship network of co-authors of Joseph M. Gozgit

This figure shows the co-authorship network connecting the top 25 collaborators of Joseph M. Gozgit. A scholar is included among the top collaborators of Joseph M. Gozgit based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joseph M. Gozgit. Joseph M. Gozgit is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gozgit, Joseph M., Youngchul Song, Scott Wardwell, et al.. (2018). RET fusions observed in lung and colorectal cancers are sensitive to ponatinib. Oncotarget. 9(51). 29654–29664. 19 indexed citations

Rivera, Victor M., Susan Branford, Franck E. Nicolini, et al.. (2015). A Multi-Institutional Retrospective Analysis of Tyrosine Kinase Inhibitor (TKI) Clinical and Preclinical Efficacy According to BCR-ABL Mutation Status in CP-CML Patients. Blood. 126(23). 2790–2790. 2 indexed citations

Marek, Lindsay A., Trista K. Hinz, Anne von Mäßenhausen, et al.. (2014). Nonamplified FGFR1 Is a Growth Driver in Malignant Pleural Mesothelioma. Molecular Cancer Research. 12(10). 1460–1469. 33 indexed citations

Wynes, Murry W., Trista K. Hinz, Dexiang Gao, et al.. (2014). FGFR1 mRNA and Protein Expression, not Gene Copy Number, Predict FGFR TKI Sensitivity across All Lung Cancer Histologies. Clinical Cancer Research. 20(12). 3299–3309. 125 indexed citations

Garner, Andrew P., Joseph M. Gozgit, Rana Anjum, et al.. (2014). Ponatinib Inhibits Polyclonal Drug-Resistant KIT Oncoproteins and Shows Therapeutic Potential in Heavily Pretreated Gastrointestinal Stromal Tumor (GIST) Patients. Clinical Cancer Research. 20(22). 5745–5755. 123 indexed citations

Pentecost, Brian T., Joseph M. Gozgit, Brooke Bentley, et al.. (2014). SKP2 Overexpression Is Associated With Increased Serine 10 Phosphorylation of p27 (pSer10p27) in Triple‐Negative Breast Cancer. Journal of Cellular Physiology. 229(9). 1160–1169. 11 indexed citations

Gozgit, Joseph M., Rachel M. Squillace, Matthew Wongchenko, et al.. (2013). Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models. Cancer Chemotherapy and Pharmacology. 71(5). 1315–1323. 50 indexed citations

Falco, Valentina De, Magesh Muthu, Liborio Torregrossa, et al.. (2013). Ponatinib (AP24534) Is a Novel Potent Inhibitor of Oncogenic RET Mutants Associated With Thyroid Cancer. The Journal of Clinical Endocrinology & Metabolism. 98(5). E811–E819. 74 indexed citations

Gozgit, Joseph M., et al.. (2013). Comprehensive Analysis Of The In Vitro Potency Of Ponatinib, and All Other Approved BCR-ABL Tyrosine Kinase Inhibitors (TKIs), Against a Panel Of Single and Compound BCR-ABL Mutants. Blood. 122(21). 3992–3992. 6 indexed citations

10.

Gozgit, Joseph M., et al.. (2013). Abstract 2084: Ponatinib is a highly potent inhibitor of activated variants of RET found in MTC and NSCLC .. Cancer Research. 73(8_Supplement). 2084–2084. 4 indexed citations

11.

Gozgit, Joseph M., Matthew J. Wong, Lauren Moran, et al.. (2012). Ponatinib (AP24534), a Multitargeted Pan-FGFR Inhibitor with Activity in Multiple FGFR-Amplified or Mutated Cancer Models. Molecular Cancer Therapeutics. 11(3). 690–699. 273 indexed citations

12.

Turk, Casey, Joseph M. Gozgit, Christopher N. Otis, et al.. (2012). Paralemmin-1 is over-expressed in estrogen-receptor positive breast cancers. Cancer Cell International. 12(1). 17–17. 8 indexed citations

13.

Schrock, Alexa B., Joseph M. Gozgit, & Victor M. Rivera. (2012). Abstract B15: The pan-BCR-ABL inhibitor ponatinib inhibits viability of gatekeeper mutant BCR-ABLT315I cells with greater potency than a nilotinib/MEK inhibitor combination. Clinical Cancer Research. 18(10_Supplement). B15–B15. 2 indexed citations

14.

Gozgit, Joseph M., Matthew J. Wong, Scott Wardwell, et al.. (2011). Potent Activity of Ponatinib (AP24534) in Models of FLT3-Driven Acute Myeloid Leukemia and Other Hematologic Malignancies. Molecular Cancer Therapeutics. 10(6). 1028–1035. 110 indexed citations

15.

Gozgit, Joseph M., Geraldine Bebernitz, Minwei Ye, et al.. (2008). Effects of the JAK2 Inhibitor, AZ960, on Pim/BAD/BCL-xL Survival Signaling in the Human JAK2 V617F Cell Line SET-2. Journal of Biological Chemistry. 283(47). 32334–32343. 77 indexed citations

16.

Gozgit, Joseph M., Geraldine Bebernitz, Minwei Ye, et al.. (2007). Effects of a Novel, Selective Jak2 Inhibitor, AZ60, on STAT5 Signaling and Cellular Growth in Jak2 V617F Cell Lines.. Blood. 110(11). 3549–3549. 1 indexed citations

17.

Gozgit, Joseph M., et al.. (2007). PLD1 is overexpressed in an ER-negative MCF-7 cell line variant and a subset of phospho-Akt-negative breast carcinomas. British Journal of Cancer. 97(6). 809–817. 37 indexed citations

18.

Turk, Casey, et al.. (2006). Alpha-fetoprotein derived growth inhibitory peptide (GIP) inhibits expression of cyclin E1. Cancer Research. 66. 1155–1155. 2 indexed citations

19.

Gozgit, Joseph M., et al.. (2006). Use of an Aggressive MCF-7 Cell Line Variant, TMX2-28, to Study Cell Invasion in Breast Cancer. Molecular Cancer Research. 4(12). 905–913. 49 indexed citations

20.

Gozgit, Joseph M., et al.. (2004). Differential action of polycyclic aromatic hydrocarbons on endogenous estrogen-responsive genes and on a transfected estrogen-responsive reporter in MCF-7 cells. Toxicology and Applied Pharmacology. 196(1). 58–67. 80 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact